Brief: Gilead Says Co Will Acquire Remaining Worldwide Rights Of Trodelvy® From Everest Medicines

Everest Medicines

16/08/2022 24:19

Aug 15 (Reuters) - Gilead Sciences Inc  GILD.O :
    * GILEAD TO ACQUIRE REMAINING WORLDWIDE RIGHTS OF TRODELVY®
    * GILEAD SCIENCES-ASSUME RESPONSIBILITY FOR CLINICAL
DEVELOPMENT,COMMERCIALIZATION IN GREATER CHINA AND SOUTH KOREA,
AMONG OTHER ASIAN MARKETS
    * UNDER TERMS OF AGREEMENT, GILEAD WILL MAKE A $280 MILLION
UPFRONT PAYMENT TO EVEREST
    * GILEAD - EVEREST IS ELIGIBLE TO RECEIVE UP TO $175 MILLION
IN
POTENTIAL ADDITIONAL PAYMENTS UPON ACHIEVEMENT OF CERTAIN
REGULATORY, COMMERCIAL MILESTONES
    * GILEAD WILL ALSO HAVE OPPORTUNITY TO RECRUIT EVEREST
EMPLOYEES
WORKING DIRECTLY ON TRODELVY PROGRAM

Source text for Eikon:  ID:nBw2Tnr4ya 
Further company coverage:  GILD.O 

 ((reuters.briefs@thomsonreuters.com;))